It is worth considering in this respect that conflicting results have been reported with regard to Treg frequencies in HER2- versus HER2+ breast cancers [27,41], discrepancies that could be due in part to tumor staging, but also to the different and often partial phenotypic markers used to identify regulatory T cells. This evidence concerns the gene ERBB2 and breast cancer.